Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Premier Research Worldwide [NASDAQ: PRWW] -- Ignore unavailable to you. Want to Upgrade?

To: Glenn Petersen who wrote (23)	10/15/1999 2:47:00 PM
From: Glenn Petersen	Read Replies (1) \| Respond to of 33

PRWW announces an Internet initiative: biz.yahoo.com Thursday October 14, 8:06 am Eastern Time Company Press Release SOURCE: Premier Research Worldwide, Ltd. Premier Research Worldwide Signs a Major Contract to Provide Internet (e-Enabled) Clinical Software Solutions Linking Participants in A Global Clinical Oncology Trial The Contract Validates the Company's Initiative as an e-Research Organization And Has a Potential Value of Approximately $9.5 Million PHILADELPHIA, Oct. 14 /PRNewswire/ -- Premier Research Worldwide, Ltd. (Nasdaq: PRWW - news), through its DLB Systems' Technology and Consulting division, announces the signing of a major 5-year contract to provide its integrated clinical research software and consulting services over the Internet to connect 400 worldwide investigational sites participating in a worldwide oncology trial. The Company estimates that the value of the contract over the five-year term will be approximately $9.5 million. The company believes that this is the most extensive integrated worldwide web-based trial, data and safety management solution in the clinical research industry and validates PRWW's transformation into an e-research organization. This project is for one of the top pharma companies in the world working through the Breast Cancer International Research Group (BCIRG) of Alberta, Canada. ``This contract represents the significant clinical advantages possible by combining `best in science' breast cancer treatment, `best in class' DLB software and Internet technology that together create a unique research process that connects physicians and patients worldwide,' said Joseph Esposito, President and Chief Operating Officer of PRWW. Jean Marc Nabholtz, MD, Chairman of the Breast Cancer International Research Group, Ltd. (BCIRG) commented that ``our mission to improve the outcome for breast cancer patients by establishing global partnerships with the pharmaceutical industry is enhanced by our partnership with DLB Systems of Premier Research Worldwide. DLB's innovative technology and consulting solutions are based upon a comprehensive understanding of clinical research. This collaboration will accelerate the availability of pivotal data in breast cancer trails around the world.' Joel Morganroth, M.D., Chairman and CEO of PRWW commented that ``our company is rapidly transforming itself into an e-research enterprise evidenced by the acceptance of our DLB Systems web-based technology solutions as the backbone in this global study. This approach was selected as a means to accelerate the conduct of clinical trials while simultaneously improving quality and reducing costs. PRWW's other e-research initiatives include using the Internet to accelerate patient recruitment through its relationship with AmericasDoctor.com and the rapid evolution of its worldwide central diagnostics capabilities as an Internet-based enterprise.' BCIRG is the first Academic, Global Virtual Intergroup in oncology currently comprising about five hundred investigators with the goal of improving worldwide breast cancer treatment. BCIRG comprises investigators from twenty countries from four continents, including Canada, the United States, South Africa, and twelve countries in Europe and three in South America. When a new promising oncology drug is identified by BCIRG, academic-sponsor global strategies for drug development are initiated which results in the rapid design of specific trials. BCIRG also provides data management and monitoring maintaining data independence from the pharmaceutical sponsor. Based in Philadelphia, PA, with offices in New Jersey and England, PRWW (http://www.premier-research.com) is a global service and consulting company. Through the application and integration of science, process and technology, PRWW adds significant value to its clients by enabling multiple advantages in the clinical development process, improving the quality and timeliness of data, speeding time to market and reducing overall development costs. Through coupling an in-depth understanding of clinical development with technology and efficient workflow processes, PRWW provides specific clinical development solutions for clients in the pharmaceutical, biotechnology and medical device industries as well as clinical research organizations (CROs). PRWW products and services include Targeted Therapeutic Research, Centralized Diagnostic Testing and Internet enabled Proprietary Software. The Company is also a pioneer in recruiting patients for clinical trials via the Internet and has a working relationship and minority ownership position in www.americasdoctor.com, an e-health company that is one of four anchor tenants on the AOL Health Page. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential factors that could affect the Company's financial results can be found in the Company's Registration Statement of Form S-1 and in its Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC). SOURCE: Premier Research Worldwide, Ltd.